France LEADLESS, Comprehensive Follow-up of the Leadless Stimulator AVEIR VR LP
Although the idea of a leadless pacemaker was first proposed in the 1970s to eliminate the probes, pockets and connectors required by conventional cardiac procedures and the associated complications, the first devices were not developed until the late 2010s. Leadless pacemakers can also improve patient comfort by replacing surgery with a percutaneous procedure, eliminating the mass and scar visible at the implantation site of a conventional pacemaker, and eliminating the need for activity restrictions to prevent dislodgement after implantation of a conventional lead.
The AVEIR VR LP leadless pacemaker was CE marked in July 2023 and will be implanted in patients in Europe.
The objective of this national registry is to evaluate the safety and performance of the AVEIR VR LP system in a population of patients indicated for implantation of a VVI(R) pacemaker in France. This registry will also allow the collection of patient characteristics and indications under normal conditions of use.
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)
This project concerns a population at risk of sudden death by dissection of the thoracic aorta. Its interest is to make it possible to recognize the genes that protect or worsen the evolution of aneurysms, to better understand the mechanisms involved, to detect and treat aneurysms of the thoracic aorta, wich is a pathology that is completely silent clinically until life-threatening complications.
The variability in the severity of the disease within the same family is related to modifier genes.
The objective is to find the modifying factors that account for the variability in the severity of the progression of aneurysms of the thoracic aorta.
RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Heart Failure Rehospitalization
The prevalence of heart failure (HF) is constantly increasing in France due to the aging of the population, better management of etiological factors and improved treatments (drug / interventional). On the other hand, re-hospitalizations for heart failure continue to increase, exceeding reception capacities and constitute a real challenge for current public health systems. The PRADO system provides administrative support (through a health insurance advisor) in the management of patient appointments with their doctors as well as home visits by a nurse trained in heart failure. Other interventional medical and educational interventions performed during an out-of-hospital consultation guided by a computer platform would help to optimize the care and continuity of care.
100 Clinical Results associated with French Cardiology Association
0 Patents (Medical) associated with French Cardiology Association
100 Deals associated with French Cardiology Association
100 Translational Medicine associated with French Cardiology Association